☆ 4.3 Review

Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond

ENDOCRINOLOGY AND METABOLISM (2023)

Related references

Note: Only part of the references are listed.

Review Endocrinology & Metabolism

Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease

Julian M. Yabut et al.

Summary: Glucagon-like peptide-1 (GLP-1) plays a significant role in improving liver health and is associated with the treatment of type 2 diabetes (T2D) and obesity using GLP-1 receptor agonists (GLP-1RA). GLP-1RA can reduce hepatic inflammation, steatosis, and fibrosis. They also decrease appetite and body weight, reduce lipoprotein secretion, and attenuate systemic and tissue inflammation, thus contributing to the improvement of metabolic-associated fatty liver disease (MAFLD).

ENDOCRINE REVIEWS (2023)

Add to Collection

Article Endocrinology & Metabolism

The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment

Bertrand Cariou

Summary: Non-alcoholic fatty liver disease (NAFLD) is associated with visceral obesity, insulin resistance, and type 2 diabetes. Adipocyte dysfunction plays a key role in the molecular link between NAFLD, visceral adipose tissue, and metabolic syndrome. Strategies targeting metabolic dysfunction, such as weight loss and specific medications, are effective in treating NAFLD and related conditions.

DIABETES OBESITY & METABOLISM (2022)

Add to Collection

Review Peripheral Vascular Disease

Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management

Mohamad B. Taha et al.

Summary: Obesity is a significant burden worldwide, and glucagon-like peptide-1 receptor agonists have been shown to be effective therapies for weight loss and improving cardiometabolic risk.

CURRENT ATHEROSCLEROSIS REPORTS (2022)

Add to Collection

Article Pharmacology & Pharmacy

GLP-1-Incretin and pleiotropic hormone with pharmacotherapy potential. Increasing secretion of endogenous GLP-1 for diabetes and obesity therapy

Jens Juul Holst et al.

Summary: Stimulating the endogenous secretion of GLP-1 has potential therapeutic benefits for regulating glucose metabolism, appetite, and weight, as well as promoting the release of other related hormones. This approach shows attractiveness and feasibility.

CURRENT OPINION IN PHARMACOLOGY (2022)

Add to Collection

Review Endocrinology & Metabolism

The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD

Chandani Patel Chavez et al.

Summary: The burden of cirrhosis from nonalcoholic fatty liver disease (NAFLD) is becoming widespread in the United States. There needs to be greater awareness among endocrinologists, who often see but may miss the diagnosis in adults with obesity or type 2 diabetes mellitus (T2D) who are at high risk. Recent studies suggest that glucagon-like peptide-1 receptor agonists (GLP-1RAs) have beneficial effects on nonalcoholic steatohepatitis (NASH) in this population.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

Add to Collection

Review Endocrinology & Metabolism

GLP-1 physiology informs the pharmacotherapy of obesity

Daniel J. Drucker

Summary: GLP1RA is an effective drug for the treatment of type 2 diabetes and has potential for obesity treatment. GLP-1 reduces food intake and body weight in both animals and humans, and its mechanisms of action have been extensively studied. GLP-1-based therapies may become important options for the treatment of obesity and its complications.

MOLECULAR METABOLISM (2022)

Add to Collection

Review Peripheral Vascular Disease

GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?

Mauricio Reis Pedrosa et al.

Summary: This review discusses the evidence supporting the use of glucagon-like peptide 1 receptor agonists (GLP-1RA) to treat obesity and their role as a cardioprotective drug. GLP-1RA not only reduces cardiovascular risk, but also improves insulin resistance. Recent studies highlight the importance of GLP-1RA in the treatment of obesity and cardioprotection.

CURRENT ATHEROSCLEROSIS REPORTS (2022)

Add to Collection

Article Endocrinology & Metabolism

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Melanie J. Davies et al.

Summary: The American Diabetes Association and the European Association for the Study of Diabetes have updated the consensus statements on the management of hyperglycemia in adults with type 2 diabetes. The new recommendations highlight the importance of social determinants of health, weight management, and provide practical tips for implementation.

DIABETES CARE (2022)

Add to Collection

Review Neurosciences

The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review

Niklas Reich et al.

Summary: Currently, there is a lack of disease-modifying treatments for Alzheimer's and Parkinson's disease. However, GLP-1 mimetics have shown neuroprotective effects in preclinical studies, making them a promising treatment option for these diseases.

FRONTIERS IN NEUROSCIENCE (2022)

Add to Collection

Article Clinical Neurology

Evaluation of liraglutide in the treatment of Alzheimer's disease

Paul Edison et al.

Alzheimers & Dementia (2021)

Add to Collection

Article Endocrinology & Metabolism

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)

Juan P. Frias et al.

Summary: The study compared the efficacy and safety of different doses of dulaglutide in patients with inadequately controlled type 2 diabetes, demonstrating that higher doses of dulaglutide were more effective in reducing HbA(1c) and body weight.

DIABETES CARE (2021)

Add to Collection

Review Biochemistry & Molecular Biology

What Is the Mechanism Driving the Reduction of Cardiovascular Events from Glucagon-like Peptide-1 Receptor Agonists?-A Mini Review

Jared Berndt et al.

Summary: GLP-1 RAs are considered the standard of care for type 2 diabetes in many countries due to their strong anti-hyperglycemic effects and favorable safety profile. Recent CV outcome trials have shown that these molecules reduce major adverse cardiovascular events and improve surrogate markers associated with CV risk, prompting further research into their cardiovascular protective qualities.

MOLECULES (2021)

Add to Collection

Article Endocrinology & Metabolism

Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)

M. S. Capehorn et al.

DIABETES & METABOLISM (2020)

Add to Collection

Article Endocrinology & Metabolism

Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials

Mirna Abd El Aziz et al.

DIABETES OBESITY & METABOLISM (2020)

Add to Collection

Review Endocrinology & Metabolism

Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials

David M. Williams et al.

DIABETES THERAPY (2020)

Add to Collection

Review Endocrinology & Metabolism

GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art

Michael A. Nauck et al.

MOLECULAR METABOLISM (2020)

Add to Collection

Article Endocrinology & Metabolism

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events

Ildiko Lingvay et al.

BMJ OPEN DIABETES RESEARCH & CARE (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea The PIONEER 3 Randomized Clinical Trial

Julio Rosenstock et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)

Add to Collection

Article Endocrinology & Metabolism

Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

Bo Ahren et al.

DIABETES OBESITY & METABOLISM (2018)

Add to Collection

Article Endocrinology & Metabolism

Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme

K. Cusi et al.

DIABETIC MEDICINE (2018)

Add to Collection

Review Clinical Neurology

Examining the 'psychopharmacology revolution' (1950-1980) through the advertising of psychoactive drugs in the British Medical Journal

A. Richard Green et al.

JOURNAL OF PSYCHOPHARMACOLOGY (2018)

Add to Collection

Article Cell Biology

Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist

Stephen T. Buckley et al.

SCIENCE TRANSLATIONAL MEDICINE (2018)

Add to Collection

Article Endocrinology & Metabolism

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

Andrew J. Ahmann et al.

DIABETES CARE (2018)

Add to Collection

Article Endocrinology & Metabolism

Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials

Karolin Bettge et al.

DIABETES OBESITY & METABOLISM (2017)

Add to Collection

Article Endocrinology & Metabolism

Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study

Jean-Michel Petit et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)

Add to Collection

Review Endocrinology & Metabolism

Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes

Giovanna Muscogiuri et al.

TRENDS IN ENDOCRINOLOGY AND METABOLISM (2017)

Add to Collection

Article Pharmacology & Pharmacy

Comparing Adoption of Breakthrough and Me-too Drugs Among Medicare Beneficiaries: a Case Study of Dipeptidyl Peptidase-4 Inhibitors

Inmaculada Hernandez et al.

JOURNAL OF PHARMACEUTICAL INNOVATION (2017)

Add to Collection

Article Endocrinology & Metabolism

Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial

Michael Nauck et al.

DIABETES CARE (2016)

Add to Collection

Article Chemistry, Medicinal

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

Jesper Lau et al.

JOURNAL OF MEDICINAL CHEMISTRY (2015)

Add to Collection

© Peeref 2019-2024. All rights reserved.